Skip to main content

Table 1 Baseline patient characteristics

From: Pulmonary vasodilation by sildenafil in acute intermediate-high risk pulmonary embolism: a randomized explorative trial

 

Placebo (SD)

Sildenafil (SD)

p-value

n = 10

n = 10

Age (years)

72 (9)

63 (9)

0.09

Female (%)

50

30

0.51

Height (cm)

170 (10)

171 (7)

0.87

Weight (kg)

87 (13)

86 (10)

0.83

BMI (kg/m2)

30 (3)

30 (4)

0.77

Known active cancer (%)

0

0

1.00

Immobilisation (%)

10

20

0.59

Recent surgery/trauma (%)

10

20

0.59

Previous VTE (%)

50

10

0.04

COPD (%)

0

20

0.17

DM (%)

30

10

0.17

Smoking (%)

10

10

1.00

Estrogen (%)

10

10

1.00

Duration of symptoms (d)

3.0 (1.3)

2.7 (1.3)

0.66

UFH/LMH/VKA/NOAK (n)

2/7/0/1

0/9/0/1

na

Oxygen therapy (l)

1.8 (1.4)

1.9 (1.9)

0.85

TnT (ng/l)

198 (131)

136 (150)

0.66

NT proBNP (ng/l)

6573 (8624)

1201 (113)

0.08

RF (/min)

18 (3)

19 (3)

0.19

Periferal saturation (%)

96 (2)

95 (2)

0.13

Pulse (BPM)

70 (9)

85 (12)

0.02

BPs (mmHg)

134 (10)

137 (24)

0.55

BPd (mmHg)

81 (9)

88 (12)

0.25

RV diameter* (cm)

5.4 (0.5)

5.2 (0.8)

0.70

LV diameter* (cm)

3.7 (0.5)

3.2 (0.5)

0.06

RV/LV*

1.5 (0.3)

1.7 (0.5)

0.23

  1. BMI body mass index, VTE venous thrombus embolism, COPD chronic obstructive pulmonary disease, DM diabetes mellitus, UFH unfractioned heparin, LMH low molecular weight heparin, VKA vitamin-K antagonist, NOAK non-vitamin-K oral anti-coagulation, TnT troponin-T, NT-proBNP N-terminal pro brain natriuretic peptide, RF respiratory frequency, BPs systolic blood pressure, BPd diastolic blood pressure, RV righ ventricle, LV left ventricle, RV/LV right ventricular/left ventricular diameter ratio, *measured by computed tomography at the day of screening for inclusion. Data is reported as mean ± SD